>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

5.37 -0.10 (-1.83%) 09/16/2026
Abeona Therapeutics Inc. (ABEO)
Performance
Historical returns
1D
-1.83%
1W
-2.01%
1M
-9.60%
3M
-4.96%
6M
8.48%
1Y
-5.46%
5Y
-82.68%
Snapshot
Key statistics
Close
5.37
Change
-0.10
Change %
-1.83%
Open
5.51
Day Range
5.22 – 5.55
Volume
1,903,069
Avg Vol (20d)
1,195,760
Rel Vol
1.59x
52W Range
4.00 - 7.65
vs 52W High
-29.80%
vs 52W Low
34.25%
Gap
-0.05
Market Cap
USD 306.06M
Beta
1.12
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
8 bullish · 5 bearish points
Bullish view
  • Operating margin expanded to -120.0% in the Jun 2026 quarter from -5,698.0% a year earlier.
  • Revenue grew 2,745.0% year on year in the Jun 2026 quarter to $11.38M.
  • Consensus looks for 2,988.0% revenue growth in 2028 to $179.72M.
  • Beat consensus EPS in 7 of the last 8 quarters.
  • Has recovered 28.8% off the 52-week low of $4.17.
  • Trades at just 14.3× the 2028 consensus EPS of $0.38.
  • Consensus has EPS compounding 144.0% a year to $2.23 by 2030, which grows the multiple down to 2.4×.
  • Sits 229.0% below the average analyst target of $17.67 across 3 firms.
Bearish view
  • Gross margin slipped to 63.3% from 75.0% a year ago.
  • FY2025 earnings fell 211.7% to $71.18M.
  • The Q2 '26 quarter missed on EPS by $0.12 (51.1% below consensus).
  • Revenue in the same quarter came in $858.4K short of consensus.
  • Still 28.0% below its 52-week high of $7.46.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 16
2026
$5.37 1.83%Latest
Abeona Therapeutics fell 1.83% to $5.37, on 1.6× average volume. Roughly 1.3 points were stock-specific — the S&P 500 fell 0.44% while Healthcare peers (XLV) rose 0.07% alongside it. The move left the stock 28.0% below its 52-week high.
Sep 10
2026
$5.48 5.35%
Abeona Therapeutics fell 5.35% to $5.48, its biggest one-day drop in 4 weeks and a 1.5σ move against its 60-day volatility, on 1.5× average volume. This was largely stock-specific: the S&P 500 fell 0.60% while Healthcare peers (XLV) fell 0.55% that session, leaving about 4.7 points of the move unexplained by the market after adjusting for a 1.12 beta. Shares opened with a 1.21% gap down, lost their 200-day moving average and marked a 3rd consecutive decline. Historically, after 1.5σ-or-larger down days, Abeona Therapeutics returned -0.19% on average over the following 5 sessions (47% positive, n=34).
Aug 26
2026
$6.01 3.22%
Abeona Therapeutics fell 3.22% to $6.01. Roughly 2.2 points were stock-specific — the S&P 500 gained 0.02% while Healthcare peers (XLV) fell 1.00% alongside it. Shares closed near the session low (6% of the day's range).
Aug 20
2026
$5.96 2.77%
Abeona Therapeutics fell 2.77% to $5.96. The move was broadly in line with its sector — the S&P 500 fell 0.84% while Healthcare peers (XLV) fell 1.87% the same session — so little of it was company-specific. Shares opened with a 1.14% gap down and closed near the session low (2% of the day's range).
Aug 18
2026
$6.16 3.70%
Abeona Therapeutics rose 3.70% to $6.16. Roughly 2.1 points were stock-specific — the S&P 500 fell 0.68% while Healthcare peers (XLV) rose 1.60% alongside it.
Aug 17
2026
$5.94 0.75%Earnings
Abeona Therapeutics fell 0.75% to $5.94. Shares opened with a 2.42% gap down and marked a 3rd consecutive decline. It came 2 sessions after the Q2 2026 print.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month5.22 +2.87%
on 09/16/26
Open 5.94
6.32 -15.03%
on 08/19/26
-0.57 (-9.60%)
since 08/17/26
3-Month5.22 +2.87%
on 09/16/26
Open 5.65
7.65 -29.80%
on 08/11/26
-0.28 (-4.96%)
since 06/16/26
6-Month4.23 +26.95%
on 03/30/26
Open 4.76
7.65 -29.80%
on 08/11/26
+0.61 (+12.82%)
since 03/17/26
YTD4.23 +26.95%
on 03/30/26
Open 5.31
7.65 -29.80%
on 08/11/26
+0.06 (+1.13%)
since 01/02/26
52-Week4.00 +34.25%
on 11/07/25
Open 5.73
7.65 -29.80%
on 08/11/26
-0.36 (-6.28%)
since 09/15/25
5-Year2.19 +145.21%
on 02/24/23
Open 31.25
33.25 -83.85%
on 09/09/21
-25.88 (-82.82%)
since 09/08/21
New Highs
Historical highs
5-Day
0×
-2.01% from peak
1-Month
1×
-13.53% from peak
3-Month
9×
-28.02% from peak
6-Month
18×
-28.02% from peak
YTD
13×
-28.02% from peak
52-Week
10×
-28.02% from peak
2-Year
12×
-28.02% from peak
3-Year
25×
-38.13% from peak
5-Year
0×
-83.48% from peak
10-Year
23×
-99.00% from peak
Financial SnapshotFY 2025
Full financials
Revenue
USD 5.82M
Net Income
USD 71.18M
-211.7% YoY
EPS
1.34
-186.5% YoY
Gross Margin
73.7%
Operating Margin
-1,536.9%
Net Margin
1,223.1%
EBITDA
USD 78.59M
Free Cash Flow
-USD 84.30M
-1,448.5% margin
ROE
44.7%
ROA
32.4%
Debt / Equity
0.16x
net debt -USD 53.47M
Cash & Equiv.
USD 78.44M
News
All news
09/16 16:31 ET · seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
09/16 07:30 ET · globenewswire.com
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville,...
09/15 17:00 ET · globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).
09/08 23:26 ET · businesswire.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.
09/02 07:30 ET · globenewswire.com
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:
09/01 07:30 ET · globenewswire.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
08/13 15:57 ET · seekingalpha.com
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity
Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed analyst expectations, leading to a 14% stock drop. Operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, highlight a steep learning curve, but management expects...
08/13 12:47 ET · seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Market News ×
Loading news…